Shared on05 Sep 25
With both future P/E and net profit margin holding steady, analyst valuation for Caplin Point Laboratories remains unchanged, maintaining the price target at ₹2508. What's in the News Board meeting scheduled to consider quarterly unaudited financial results for the quarter ended June 30, 2025.
Shared on24 Apr 25
AnalystConsensusTarget made no meaningful changes to valuation assumptions.
Shared on17 Apr 25
AnalystConsensusTarget made no meaningful changes to valuation assumptions.
Shared on09 Apr 25Fair value Increased 0.68%
AnalystConsensusTarget made no meaningful changes to valuation assumptions.
Shared on26 Mar 25Fair value Decreased 0.93%
AnalystConsensusTarget has increased revenue growth from 14.2% to 16.5% and decreased future PE multiple from 34.0x to 30.5x.